Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials
AL Catapano, LV Lee, MJ Louie, D Thompson… - Scientific reports, 2017 - nature.com
Low-density lipoprotein cholesterol (LDL-C) reductions with the PCSK9 monoclonal
antibody alirocumab may be affected by background statin dose due to increased PCSK9 …
antibody alirocumab may be affected by background statin dose due to increased PCSK9 …
Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
Purpose Evolocumab significantly reduces low-density lipoprotein-cholesterol (LDL-C); we
investigated its effects on LDL-C lowering in patients with mixed hyperlipidemia. Methods …
investigated its effects on LDL-C lowering in patients with mixed hyperlipidemia. Methods …
Counterpoint: soy protein
D Jenkins - Journal of Clinical Lipidology, 2017 - lipidjournal.com
Available proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors are human monoclonal
antibodies that produce remarkable reductions in low-density lipoprotein cholesterol (LDL …
antibodies that produce remarkable reductions in low-density lipoprotein cholesterol (LDL …
Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS …
U Laufs, AL Birkenfeld, U Fraass, B Hohenstein… - … Drugs and Therapy, 2024 - Springer
Abstract Aim The PERI-DYS study aims to characterize two groups of patients with
dyslipidaemia at very high CV risk: PCSK9i receivers and patients qualifying for but not …
dyslipidaemia at very high CV risk: PCSK9i receivers and patients qualifying for but not …
Relationship between alirocumab, PCSK9 and LDL-C levels: results from the odyssey mono phase 3 trial of alirocumab 75 mg every 2 weeks
M Farnier, JJP Kastelein, E Roth… - …, 2014 - atherosclerosis-journal.com
Objectives: To understand impact of alirocumab 75 or 150 mg every 2 weeks (Q2W) when
used as monotherapy, we assessed the relationship between LDL-C, free PCSK9 and …
used as monotherapy, we assessed the relationship between LDL-C, free PCSK9 and …
Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels–experimental and clinical approaches with lipid-lowering agents
C Macchi, M Banach, A Corsini… - European Journal of …, 2019 - academic.oup.com
Regulation of pro-protein convertase subtilisin/kexin type 9 (PCSK9) by drugs has led to the
development of a still small number of agents with powerful activity on low-density …
development of a still small number of agents with powerful activity on low-density …
[HTML][HTML] PCSK9 inhibitors: a new era of lipid lowering therapy
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …
(CVD). The recent American College of Cardiology and American Heart Association …
Effect of different types and dosages of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein (a) levels: a network meta-analysis
Z Yu, L Hu, C Sun, Z Wang, X Zhang… - Journal of …, 2023 - journals.lww.com
Abstract Lipoprotein (a)[Lp (a)] has become an important component of the residual risk of
cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors …
cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors …
Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus
LT Fischer, DA Hochfellner, L Knoll, T Pöttler… - Cardiovascular …, 2021 - Springer
Background The lipid-lowering and positive cardiovascular effect of proprotein convertase
subtilisin kexin type 9 (PCSK9) inhibitors was shown in several studies, hence, they are …
subtilisin kexin type 9 (PCSK9) inhibitors was shown in several studies, hence, they are …
[HTML][HTML] Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized …
EM Roth, MR Taskinen, HN Ginsberg… - International journal of …, 2014 - Elsevier
Background Efficacy and safety of alirocumab were compared with ezetimibe in
hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other …
hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other …